Evidence map›Paper›PMID 40022263›Full record

ArticleBMC pharmacology & toxicology2025

Prodelphinidin B-2,3,3"-O-gallate via chemical oxidation of epigallocatechin-3-gallate shows high efficacy inhibiting triple-negative breast cancer cells.

Jing Wang, Yuna Wang, Shuanggou Zhang, Hongtao Hu, Ruohan Zhang, Chengting Zi, Jun Sheng, Peiyuan Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing Wang *Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China.
Yuna Wang *Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China.
Shuanggou Zhang *Key Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China.
Hongtao HuKey Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China.
Ruohan ZhangKey Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China.
Chengting ZiKey Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China. zichengting@126.com.
Jun ShengKey Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China. shengj@ynau.edu.cn.
Peiyuan SunKey Laboratory of Pu-er Tea Science, Ministry of Education, Yunnan Agricultural University, Kunming, 650201, China. sunxingjia8888@126.com.

Funding

the Project of International Science and Technology Specialists for Yunnan Province 202403AK140041the Project of the Yunnan Province Agricultural Basic Research Joint Foundation 202401BD070001-056the Yunnan Fundamental Research Project 202201AU070177
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer is a clinically aggressive malignancy with poorer outcomes versus other subtypes of breast cancer. Numerous reports have discussed the use of epigallocatechin-3-gallate (EGCG) against various types of cancer. However, the effectiveness of EGCG is limited by its high oxidation and instability. The Notch pathway is critical in breast cancer development and prognosis, and its inhibition is a potential treatment strategy.

resultsIn this study, we investigated the effects of prodelphinidin B-2,3,3''-O-gallate (named PB2,3,3''/OG or compound 2) via chemical oxidation of EGCG on cell viability and the Notch1 signaling pathway in breast cancer cells. We found that compound 2 showed significant cytotoxicity against triple-negative breast cancer cells, with the half maximal inhibitory concentration (IC

conclusionOur finding suggested that compound 2 may be a promising agent for the development of novel anti-cancer therapy options.

Indexed as

Antineoplastic AgentsCatechinTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalFemaleHumansMiceMice, Inbred BALB CMice, NudeOxidation-ReductionReceptor, Notch1Signal TransductionAntineoplastic AgentsCatechinepigallocatechin gallateNOTCH1 protein, humanReceptor, Notch1ApoptosisCell viabilityNotch1Prodelphinidin B-2,3,3''-O-gallateTriple-negative breast cancer

Identifiers

PMID40022263
PMCPMC11869402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.